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There are no data on the effects of different growth media on polyene-induced postantifungal effect (PAFE)
in Candida species. Hence, the nystatin- and amphotericin B-induced PAFEs in six Candida species (26 isolates)
grown in Sabouraud’s dextrose broth (SAB) and RPMI broth were evaluated, following limited exposure to the
MICs of the two polyenes, using an automated turbidometric method. For nystatin, PAFE varied between 1.88
and 4.87 h in SAB and 0.66 and 6.89 h in RPMI, and for amphotericin B, the equivalent values were 3.13 to
10.98 h in SAB and 0.97 to 7.01 h in RPMI. These highly significant (P < 0.001) variations in the PAFE with
both drugs, noted with most Candida strains grown in different media, call for standardization of intralabo-
ratory methodology in measuring this parameter in order to obtain universally comparable data.
Opportunistic oral infections caused by both Candida albi-
cans and non-C. albicans Candida species are becoming in-
creasingly common in immunocompromised patients. For
instance, the vast majority of human immunodeficiency virus-
infected patients suffer from oral candidosis, the most common
AIDS-associated oral infection, during the course of their dis-
ease (1).
Nystatin and amphotericin B, which belong to the polyene
group of antimycotics, are common therapeutic agents for oro-
pharyngeal candidosis (5). Nystatin is widely used as a topical
agent in the management of oral candidosis, and oral applica-
tion of this antimycotic can also be of considerable benefit in
preventing the systemic spread of oral candidosis in immuno-
compromised persons (5). Though not popular, topical ampho-
tericin B oral preparations are available and used by some
clinicians for the management of oral candidosis (5). However,
due to the diluent effect of saliva and the cleansing effect of the
oral musculature, their availability tends to fall below the ef-
fective therapeutic concentrations and the organisms undergo
only a brief exposure to antifungal agents (7). Hence, the term
“postantifungal effect” (PAFE) has been used in recent years
to describe the suppression of fungal growth that persists after
brief exposure of organisms to the antifungal agent in question.
PAFE could be used as a secondary benchmark in determining
the antifungal activity of an antimycotic in addition to the
conventional MIC measurement. It may also have therapeutic
relevance in determining the antifungal dosing regimens in a
clinical setting (2).
There are only a few reports on the PAFE of polyene anti-
fungal agents, particularly with non-C. albicans Candida iso-
lates. These studies to determine the PAFE have essentially
investigated the interactions of a few isolates with mainly a
single polyene agent (4, 10, 11). There is also no comprehen-
sive information on amphotericn B-induced PAFE on different
oral Candida species or the impact of growth media on the
PAFE. Hence, the aim of this study was to compare the PAFE
on oral isolates of Candida belonging to six different species
following limited exposure to nystatin and amphotericin B in
two commonly used growth media, namely, Sabouraud’s dex-
trose broth (SAB) and RPMI 1640 broth.
A total of 26 Candida isolates were studied: four isolates
each of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C.
krusei, and C. guilliermondii, plus C. albicans ATCC 90028 and
C. tropicalis ATCC 13803 used as the reference laboratory
strains. All isolates were identified using API-20C AUX (Bio-
Me´rieux, Basingstoke, United Kingdom). Stock cultures were
maintained at 270°C. After recovery, these were maintained
on Sabouraud’s dextrose agar and stored at 4 to 6°C during the
experimental period.
Nystatin and amphotericin B (both from Sigma, St. Louis,
Mo.) were dissolved in a mixture of dimethyl sulfoxide
(DMSO) and absolute ethanol (3:2 ratio), respectively. They
were prepared initially as 2,000-mg/ml solutions and stored at
270°C before use. Since the antifungal agents used were dis-
solved in DMSO and absolute ethanol, equivalent amounts of
the latter chemicals were tested to ascertain whether they had
an effect on the isolates tested. The minute volumes of the
chemicals used did not have any effect on yeast growth com-
pared with the controls.
SAB (Oxoid, Unipath Ltd, Basingstoke, Hampshire, En-
gland) was prepared with double-distilled, sterile water. RPMI
1640 medium, buffered with 0.165 M MOPS [3-(N-morpho-
lino)propanesulfonic acid] containing L-glutamine and lacking
sodium bicarbonate (Gibco BRL Products, Life Technology,
Gaithersburg, Md.), was dissolved in 1 liter of sterile distilled
water, adjusted to pH 7.2, and filter sterilized.
MICs of nystatin and amphotericin B for each isolate were
determined in duplicate using the twofold broth microdilution
technique as outlined by the National Committee for Clinical
Laboratory Standards (9). Both RPMI 1640 and SAB were
used to determine the MIC. In brief, 10 ml of the 1 3 105- to
5 3 105-CFU/ml inoculum of the cell suspension was inocu-
lated into each well of a 96-well microplate containing 150 ml
of medium with a twofold-diluted concentration of the drug.
The MIC was read as the highest dilution of the drug that
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inhibited growth after 24 h of incubation at 37°C in a shaking
incubator (Lab-Line).
For the PAFE assay, yeast cells maintained on Sabouraud’s
dextrose agar were inoculated onto fresh plates and incubated
overnight prior to use. The organisms were harvested, and a
cell suspension was prepared in 0.15 M phosphate-buffered
saline (pH 7.2; PBS) to an optical density at 520 nm of 1.5.
From this cell suspension, 0.5 ml was added to tubes containing
2 ml of medium (control) and 2 ml of medium-drug solution
(test): the drug concentration was the MIC of the drug. This
gave a cell suspension of 106 to 107 cells/ml in each assay tube.
The control and test tubes were then incubated at 37°C for
1 h in a shaker incubator. Following this procedure, the drug
that was carried over and contaminating the yeast cells was
removed by two cycles of centrifugation for 10 min at 3,000
rpm. The supernatant was completely decanted, and the pellets
were resuspended in 2.5 ml of sterile PBS. This procedure has
been shown to reduce the concentration of the drug as much as
10,000-fold (2), thereby greatly minimizing any carryover effect
of the drug following its removal.
An aliquot of 100 ml from each cell suspension was added
to a microtiter well containing 150 ml of medium. Then the
microtiter plate was placed in a computerized spectrophoto-
metric incubator (Spectramax 340; Molecular Devices Corp.,
Sunnyvale, Calif.) and incubated at 37°C for 24 h. Plates were
kept stationary on the automated reader but were automati-
cally shaken at 30-min intervals immediately prior to the op-
tical density readings. Growth of yeast cells was automatically
monitored by the computerized instrument in terms of the
change in the turbidity (absorbance at 595 nm) at 30-min
intervals. The PAFE was determined as the difference in time
(in hours) required for the growth of the drug-free control and
drug-exposed test cultures to increase to a 0.05 absorbance
level, i.e., the time required for the turbidity of the yeast
cell-suspension in the test culture to reach the 0.05 absorbance
level minus the time required for the turbidity of the drug-free
control culture to increase to the 0.05 absorbance level (3, 4,
6). In our hands the foregoing turbidometric assessment of
PAFE has proven to be highly sensitive and reproducible (3,
6). Student’s t test was used to analyze the data.
The MICs (24 h) for all tested isolates in SAB and RPMI
1640 broth for nystatin ranged between 1.56 and 6.25 mg/ml,
while the corresponding values for amphotericin B ranged
between 0.049 and 0.78 mg/ml. These MICs were all within the
reported in vitro susceptibility values for nystatin and ampho-
tericin B (8), implying that all tested isolates were susceptible
to the latter polyenes.
The PAFEs of nystatin on the 26 isolates ranged between
1.88 and 4.87 h in SAB broth and 0.66 and 6.89 h in RPMI
broth, whereas equivalent figures for amphotericin B were 3.13
to 10.98 h in SAB and 0.97 to 7.01 h in RPMI broth (Table 1).
These differences in the PAFE values when yeasts were cul-
tured in the two different media were highly significant (P ,
0.001) for both nystatin and amphotericin B, with the exception
of the amphotericin B-induced PAFE observed with C. albi-
cans and C. glabrata in these media (Fig. 1). A significant
interspecies variation in polyene-induced PAFE was also ob-
served (Table 1). For instance, the mean values of amphoter-
icin B-induced PAFE in SAB ranged from 3.13 (for C. gla-
brata) to 10.98 h (for C. tropicalis).
As demonstrated previously (3, 4, 6), growth curves revealed
a period of fungistasis after removal of the polyene antimycot-
ics, illustrating a PAFE, in both SAB and RPMI 1640 medium.
This was followed by a growth rate comparable to that of the
unexposed controls. However, the growth rates in the two
media were different, as shown by the different PAFE values
(Table 1 and Fig. 1).
The incidence of oral candidosis continues to escalate, with
increasing emergence of inherent or acquired resistance to
antifungal agents (12), and it would be desirable if clinicians
could rely on in vitro antifungal susceptibility tests to obtain
critical information regarding dosage regimens. The MIC of an
agent is the universally accepted criterion for evaluating dos-
age regimens, and the goal with respect to therapy with anti-
mycotics is to maintain the drug concentration above the MIC
throughout the dosing period (10). However, in reality, con-
stant drug levels in the infective focus are not easily achieved,
especially in the oral environment, where the salivary flushing
action is constant. Therefore, additional parameters to guide
and determine the dosage regimens are needed. The recently
introduced concept of PAFE may serve as a further benchmark
in this context together with MIC determinations.
Although a reasonable database on the PAFE of the major
antifungals against a number of Candida species is available (3,
4, 6), the impact of different growth media on the PAFE of
these antimycotics has not been studied. The media used in our
study, namely, SAB and RPMI 1640 broth, differ in their com-
position and their pH. SAB contains pancreatic digest of ca-
sein, peptic digest of fresh meat, and dextrose, and its pH is 5.7
(Oxoid manual). RPMI 1640 broth is a chemically defined





SAB RPMI SAB RPMI
C. albicans (5) 1.88 (0.08) 3.09 (0.24) 4.36 (0.38) 4.55 (0.91)
C. glabrata (4) 2.63 (0.08) 3.39 (0.26) 3.13 (0.49) 2.70 (0.26)
C. guilliermondii (4) 3.70 (0.37) 1.71 (0.21) 5.71 (1.09) 1.11 (0.14)
C. krusei (4) 4.87 (0.18) 6.89 (0.33) 3.40 (0.23) 7.01 (0.75)
C. parapsilosis (4) 3.18 (0.20) 5.64 (0.94) 7.51 (0.61) 4.48 (0.63)
C. tropicalis (5) 3.14 (0.24) 0.66 (0.08) 10.98 (0.97) 0.97 (0.19)
a In hours. Data are means for three experiments conducted on separate occasions in duplicate for each isolate (i.e., means of 30 raw values for C. albicans and C.
tropicalis and 24 values for the other species).










medium which contains a range of amino acids, vitamins, salt,
and glucose, and its pH is 7.2 (Gibco BRL product guide). SAB
is the recommended supporting medium for laboratory culture
of fungi and has been so used for decades (2). RPMI 1640, on
the other hand, was originally formulated for suspension cul-
tures or monolayer cultures of human leukemic cells. It was
subsequently recommended as the medium of choice for anti-
fungal susceptibility testing by the National Committee for
Clinical Laboratory Standards (9). Both these media are used
extensively in mycological research, especially in studies of
Candida.
Our results indicate clearly that the growth patterns of the
isolates in SAB and RPMI 1640 broth were variable and elic-
ited different PAFE values depending on the medium, even
with the same Candida isolate. In general, Candida growth was
extensive in SAB, whereas it was comparatively low in RPMI
1640. One reason for this may be the limited nutritional
sources in RPMI 1640 broth compared with SAB. Despite the
differences in the media, a PAFE was observed for all isolates
following brief exposure to the polyenes, and this is likely to be
due to the time taken by Candida to recover before active
multiplication after such exposure. Similar polyene-induced
PAFE values have been observed, particularly with C. albicans,
in previous studies (3, 4, 6). However, this study is the first to
report the significant differences in the polyene-induced PAFE
on a battery of six different Candida species in different growth
media.
The present results therefore clearly illustrate that standard-
ization of laboratory regimens is essential in order to obtain
globally comparable data on PAFE of antimycotic agents. As
only a few reports from a handful of laboratories on the subject
of PAFE are yet available, authorities such as the NCCLS
should take early steps to design and issue guidelines (akin to
that for MIC measurement of antifungals) that could be uni-
versally used in evaluation of the PAFE and to generate data
that are globally acceptable.
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